GBC Blog

BERKELEY, US – MAINZ, Germany – March 27, 2025 — Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today the first patient has been enrolled in eAArly DETECT 2, a feasibility study to evaluate the Company’s next-generation colorectal cancer (CRC) test. The…

NEW YORK – Guardant Health announced Tuesday that its Shield blood test for colorectal cancer screening has received Advanced Diagnostic Laboratory Test (ADLT) status from the US Centers for Medicare and Medicaid Services. The test will be reimbursed at the price of $1,495 per test for Medicare patients during the initial nine-month ADLT period starting…

The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry entitled “E6(R3) Guideline for Good Clinical Practice.”  The draft guidance was prepared under the auspices of the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH).  The draft guidance outlines modernized Good Clinical…

JOIN WITH THE AACR TO FIND BETTER WAYS TO PREVENT AND TREAT CERVICAL CANCER

NEW YORK, Aug 8 (Reuters) – Recursion Pharmaceuticals (RXRX.O), opens new tab, a biotech firm which uses artificial intelligence to discover new drug candidates, has agreed to buy smaller rival Exscientia (EXAI.O), opens new tab for $688 million in an all-stock deal, according to a statement seen by Reuters. The deal, which is expected to be announced as…

Researchers at the Fred Hutchinson Cancer Center have unveiled a new type of blood test used to detect colorectal cancer, with high hopes not only in its ability to reduce barriers to testing for this particular disease, but also potentially pave the way for many other types of cancer screenings. The study, published last week in the…

SEATTLE — March 20, 2024 — Researchers at Fred Hutchinson Cancer Center have found that a specific subtype of a microbe commonly found in the mouth is able to travel to the gut and grow within colorectal cancer tumors. This microbe is also a culprit for driving cancer progression and leads to poorer patient outcomes after cancer…

Read the KLAS Research ‘US Digital Pathology 2023’ Performance Insights report. Philips has helped more than 300 customers transition to a fully digital workflow, with many more using Philips IntelliSite Pathology solution as an open platform for primary diagnosis The first company to introduce an FDA-approved digital pathology slide scanner for primary diagnostic use in 2017, Philips is one…

A team of researchers have identified epigenomic drivers associated with cancer development and progression, constructing a pan-cancer epigenetic and transcriptomic atlas from the data. This atlas “provides a foundation for further investigation of epigenetic dynamics in cancer transitions,” the study team, led by researchers from Washington University in St. Louis, wrote in Nature. The researchers used…

https://nationalcancerplan.cancer.gov/ We know that our continued progress against cancer is the direct result of advances made possible by investment from federal, state, and local governments, along with private investment, and by the sustained efforts of researchers around the world and millions of people with cancer, their caregivers, and advocates. Building on these tremendous efforts and…